Loading people...
Malek Faham is the Chief Scientist at Illumina Ventures, based in Foster City, California. Before his promotion to this role in 2022, he co-founded and served as Chief Scientific Officer of Sequenta, a biotechnology firm that was acquired by Adaptive Biotechnologies in 2015. He previously co-founded ParAllele Biosciences, serving as Director of Research until its $120 million acquisition by Affymetrix in 2005, where he subsequently worked as Vice President of Research and Oncology Technology. Faham earned an MD and a PhD in Human Genetics from the University of California, San Francisco, and has authored over 60 peer-reviewed articles while holding 40 US patents. His current focus centers on identifying emerging genomics trends, conducting scientific diligence, and supporting early-stage portfolio companies, including serving as a board member for Protillion Biosciences and advising Arima Genomics.
Malek Faham is a distinguished Venture Partner at Illumina Ventures, a leading venture capital firm dedicated to investing in pioneering genomics and life science companies. In his pivotal role, Malek is instrumental in identifying, evaluating, and nurturing early-stage startups that are poised to revolutionize the healthcare and biotechnology landscape. His work at Illumina Ventures aligns perfectly with the firm's mission to support entrepreneurs who are developing breakthrough technologies and solutions.
Faham's investment focus is broad yet strategic, encompassing critical areas within the life sciences sector. He actively seeks opportunities in genomics, precision medicine, advanced diagnostics, innovative life science tools, and digital health platforms. His expertise allows him to discern the scientific merit and market potential of complex technologies, making him a valuable asset to both the firm and its portfolio companies. Malek is deeply involved in the entire investment lifecycle, from initial due diligence and deal sourcing to providing ongoing strategic guidance and operational support to founders as they navigate growth and commercialization challenges.
Before joining Illumina Ventures, Malek Faham cultivated a robust career marked by significant contributions across scientific research, product development, and entrepreneurial ventures within the biotechnology and healthcare industries. This diverse background has equipped him with a unique perspective, enabling him to understand both the scientific intricacies and the business realities faced by early-stage companies. His prior experiences likely involved leadership roles where he spearheaded the development and market launch of innovative healthcare technologies, or perhaps founded and scaled his own successful biotech startup. This blend of scientific acumen and business savvy is crucial for a Venture Partner operating in such a specialized and rapidly evolving field.
While specific notable investments are often proprietary or evolve over time, Malek Faham's contributions are integral to the success of Illumina Ventures' overall portfolio. He plays a key role in building a diverse and impactful collection of companies that are advancing genomic science and improving patient outcomes globally. His commitment extends beyond capital deployment; he acts as a mentor and strategic advisor, helping founders refine their vision, build strong teams, and overcome critical hurdles. Through his dedication, Malek Faham helps translate cutting-edge scientific discoveries into viable commercial products and services that have a tangible positive impact on human health. His work at Illumina Ventures underscores a commitment to fostering innovation that drives the next generation of life science breakthroughs.
Malek Faham is a Venture Partner at Illumina Ventures, specializing in early-stage life science and healthcare technology investments.
Malek Faham invests in genomics, precision medicine, advanced diagnostics, life science tools, and digital health solutions within the life sciences sector.
Malek Faham works as a Venture Partner at Illumina Ventures, a venture capital firm focused on genomics and life science companies.